Your Article Summary
Residual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study
Journal of Human Hypertension, 06/03/09
Blacher J et al. – Treatment with antihypertensive agents, but not with lipid-lowering agents, was associated with a sizeable residual cardiovascular risk, suggesting that more efficient risk reduction strategies in hypertension should be developed as a priority.
Methods- Study of the degree of cardiovascular risk remaining in hypertension and dyslipidaemia pts treated pharmacologically
- Assessment of levels of risk factors achieved that is 'residual cardiovascular risk'
- Use of data from the Prospective Epidemiological Study of Myocardial Infarction (PRIME)
- PRIME subjects: 9649 men age 50–59 yrs, from France and Northern Ireland with 10-yr follow-up
- PRIME tested presence of specific residual cardiovascular risks of coronary heart disease, stroke, total of fatal and non-fatal cardiovascular events and cardiovascular mortality, in pts treated with antihypertensive agents or lipid-lowering agents
- In whole cohort, 796 pts developed fatal or non-fatal cardiovascular event
- Antihypertensive drug use at baseline significantly associated with total cardiovascular event risk, but not lipid-lowering drug use, after adjusting for classic risk factors
- Adjusted classic risk factors: age, smoking, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure and diabetes
- Similar results for coronary heart disease, stroke, and cardiovascular death, but neither for total death nor for non-cardiovascular death
- For any cardiovascular endpoint, residual risks did not globally differ by antihypertensive drug class prescribed at baseline
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Smoking intensity and lipoprotein abnormalities in active smokers
Journal of Clinical Lipidology, 12/18/09
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Lipids in Health and Disease, 12/18/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Improved 24-Hour Blood Pressure Control With Sirolimus Versus Calcineurin Inhibitor Based Immunosuppression in Renal Transplant Recipients
Transplantation Proceedings, 12/18/09
Zigzagged Augmentation Index in Diabetes
Clinical and Experimental Hypertension, 12/18/09
Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis
Clinical Reviews in Allergy and Immunology, 12/18/09

See Latest Articles